149 related articles for article (PubMed ID: 36804512)
1. Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.
Weich A; Rogoll D; Peschka M; Weich W; Pongracz J; Brand M; Fröhlich M; Serfling SE; Rowe SP; Kosmala A; Reiter FP; Meining A; Werner RA; Scheurlen M
Nucl Med Commun; 2023 Apr; 44(4):259-269. PubMed ID: 36804512
[TBL] [Abstract][Full Text] [Related]
2. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator.
Wang S; Bao Z; Liang QM; Long JW; Xiao ZS; Jiang ZJ; Liu B; Yang J; Long ZX
Hepatogastroenterology; 2013 Oct; 60(127):1639-46. PubMed ID: 24634935
[TBL] [Abstract][Full Text] [Related]
3. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [
Weich A; Rogoll D; Gawlas S; Mayer L; Weich W; Pongracz J; Kudlich T; Meining A; Scheurlen M
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33671498
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.
Kim JT; Li J; Jang ER; Gulhati P; Rychahou PG; Napier DL; Wang C; Weiss HL; Lee EY; Anthony L; Townsend CM; Liu C; Evers BM
Carcinogenesis; 2013 May; 34(5):953-61. PubMed ID: 23354304
[TBL] [Abstract][Full Text] [Related]
5. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
[TBL] [Abstract][Full Text] [Related]
6. Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.
Ungefroren H; Künstner A; Busch H; Franzenburg S; Luley K; Viol F; Schrader J; Konukiewitz B; Wellner UF; Meyhöfer SM; Keck T; Marquardt JU; Lehnert H
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555512
[TBL] [Abstract][Full Text] [Related]
7. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
[TBL] [Abstract][Full Text] [Related]
8. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
9. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery.
Hofland LJ; Breeman WA; Krenning EP; de Jong M; Waaijers M; van Koetsveld PM; Mäcke HR; Lamberts SW
Proc Assoc Am Physicians; 1999; 111(1):63-9. PubMed ID: 9893158
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene.
Verwijnen SM; Sillevis Smith PA; Hoeben RC; Rabelink MJ; Wiebe L; Curiel DT; Hemminki A; Krenning EP; de Jong M
Cancer Biother Radiopharm; 2004 Feb; 19(1):111-20. PubMed ID: 15068619
[TBL] [Abstract][Full Text] [Related]
12. Intraoperative detection and resection of occult neuroblastoma: a technique exploiting somatostatin receptor expression.
Martinez DA; O'Dorisio MS; O'Dorisio TM; Qualman SJ; Caniano DA; Teich S; Besner GE; King DR
J Pediatr Surg; 1995 Nov; 30(11):1580-9. PubMed ID: 8583329
[TBL] [Abstract][Full Text] [Related]
13. Distribution and functional significance of somatostatin receptors in malignant melanoma.
Lum SS; Fletcher WS; O'Dorisio MS; Nance RW; Pommier RF; Caprara M
World J Surg; 2001 Apr; 25(4):407-12. PubMed ID: 11344389
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
15. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
[TBL] [Abstract][Full Text] [Related]
16. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
Li SC; Martijn C; Cui T; Essaghir A; Luque RM; Demoulin JB; Castaño JP; Öberg K; Giandomenico V
PLoS One; 2012; 7(10):e48411. PubMed ID: 23119007
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
[TBL] [Abstract][Full Text] [Related]
18. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
19. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]